8-K ·Filed Aug 28, 2026

PHGE

BiomX Inc.
NEUTRAL
Impact 4/10
Horizondays Processed1mo ago SEC0001213900-26-095146
Actionable Insight • Neutral

Monitor for the Certificate of Amendment filing (Item 5.03 8-K) and the first day of split-adjusted trading on September 9. The reverse split does not change fundamentals but may reduce liquidity and increase volatility in the near term. Watch for any subsequent capital raise announcements that often follow reverse splits at micro-cap companies.

DirectionNeutral
Confidencehigh
Horizondays
Latest settled — T+5d
PHGE ▲ +13.06% at T+5d
NEUTRAL call ✓ call won +13.06% · α vs SPY +13.20% · entry $0.1371 → $0.1550
Next anchor: T+20d due 5d ago
Latest observation: T+15 -13.66% FF3 residual α
Entry anchored
Aug 28, 2026
via day open
T+1d
+4.30%
call +4.30% · α +4.99%
$0.1430
settled 5w ago
T+5d
+13.06%
call +13.06% · α +13.20%
$0.1550
settled 29d ago
T+20d
—
call — · α —
—
due 5d ago
T+60d
—
call — · α —
—
in 7w

Price Chart

Loading chart...

Executive Summary

BiomX Inc. announced a 1-for-10 reverse stock split, approved by stockholders on August 25, 2026, effective September 9, 2026. The split reduces outstanding shares from ~26.7M to ~2.7M and authorized shares from 750M to 150M. This is a routine capital structure adjustment to maintain NYSE American listing compliance, with no fundamental business change.

Key Facts

  • Reverse stock split ratio fixed at 1-for-10 by Board on August 28, 2026
  • Effective at 12:01 a.m. ET on September 9, 2026
  • Outstanding shares reduced from ~26.7M to ~2.7M
  • Authorized shares reduced from 750M to 150M
  • Stockholders approved at special meeting on August 25, 2026
  • No fractional shares issued; rounding up to next whole share
  • Proportionate adjustments to warrants, convertible instruments, and equity awards
  • New CUSIP number 09090D 608 assigned

Financial Impact

No financial impact; mechanical share consolidation with no change to proportional ownership

sharesOutstandingauthorizedShares

Risk Factors

  • Post-split price may not hold above NYSE American continued listing standards
  • Reduced share count could amplify price volatility
  • Potential for subsequent dilutive offering common after reverse split

Market Snapshot

Exchange
NYSE
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
0% bullish (6 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (PHGE) — Batch item 10001213900-26-095146
Document: 0001213900-26-095146-index.html0001213900-26-095146
Document: 0001213900-26-095146.txt0001213900-26-095146
8-K Filing (PHGE) — Batch item 40001213900-26-095146
Document: 0001213900-26-095146-index.html0001213900-26-095146
Document: 0001213900-26-095146.txt0001213900-26-095146
20 reports for PHGE
Performance horizon
64% Hit rate 7 of 11 directional calls best @ T+20▲ +62.36%Jun 16, 2026
Filters
Rows
Reports for PHGE — sortable, filterable
TypeNow
Sep 1, 2026
4w ago
8-K
NEUTRAL ★ 3/10
$0.1425 $1.85▲ +1198.25%▲ +1199.20%$0.3600 (+152.63%)
Aug 28, 2026
5w ago
8-K
NEUTRAL ★ 4/10
$0.1371 $0.1550▲ +13.06%▲ +13.20%$0.3600 (+162.58%)
Aug 5, 2026
8w ago
Press Release
BEARISH ★ 5/10
$0.1800 $0.1483▲ +17.61%▲ +17.96%$0.3600 (−100.00%)
Jul 28, 2026
9w ago
8-K
BEARISH ★ 8/10
$0.1834 $0.1868▼ −1.85%▲ +0.42%$0.3600 (−96.29%)
Jul 28, 2026
9w ago
Press Release
BEARISH ★ 7/10
$0.1834 $0.1868▼ −1.85%▲ +0.42%$0.3600 (−96.29%)
Jul 27, 2026
9w ago
424B5
BEARISH ★ 7/10
$0.1834 $0.1868▼ −1.85%▲ +0.42%$0.3600 (−96.29%)
Jul 8, 2026
12w ago
Press Release
NEUTRAL ★ 4/10
$0.2758 $0.2100▼ −23.86%▼ −24.72%$0.3600 (+30.53%)
Jul 2, 2026
13w ago
8-K
BEARISH ★ 6/10
$0.3190 $0.2800▲ +12.23%▲ +13.16%$0.3600 (−12.85%)
Jun 29, 2026
13w ago
S-1
BEARISH ★ 5/10
$0.3478 $0.3020▲ +13.17%▲ +13.77%$0.3600 (−3.51%)
Jun 22, 2026
14w ago
DEFA14A
NEUTRAL ★ 2/10
$0.4615 $0.3590▼ −22.21%▼ −23.22%$0.3600 (−21.99%)
Showing 10 of 20

US Market Status

Market Closed — Opens Mon (33h 38m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access